Versant Ventures
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
Business Model:
Revenue: $6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Versant Ventures Information
Geographic Data
Address: One Sansome Street
City: San Francisco
State: CA
Zip: 94104
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
3,552,464Website Global Rank
3,632Website Monthly Traffic
Twitter Followers
Description
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Contact Phone:
+14158018100
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2008 | Nexis Vision | Series A | 6M |
| 5/2020 | Ventus Therapeutics | Series A | 60M |
| 1/2006 | ForSight Labs | Venture Round | 2.4M |
| 6/2012 | Twelve | Series B | 15M |
| 9/2005 | Standard BioTools | Series D | 0 |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 9/2012 | Nuvaira | Series B | 10.6M |
| 4/2007 | ForSight Labs | Series A | 5M |
| 4/2008 | SpaceOAR | Series A | 0 |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 1/2018 | Metavention | Series C | 0 |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 12/2012 | Minerva Surgical | Venture Round | 20M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 8/2010 | Respicardia | Series C | 0 |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 8/2002 | Concuity | Series C | 16.3M |
| 5/2015 | NeuWave Medical | Series C | 25.3M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 3/2009 | Inogen | Series E | 3M |
| 6/2004 | Ablation Frontiers | Series A | 3.6M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 1/2001 | Cameron Health | Series A | - |
| 5/2016 | Nouscom | Series A | 13.6M |
| 4/2005 | ParAllele Bioscience | Convertible Note | 6M |
| 7/2008 | Hicuity Health | Series B | 5M |
| 1/2022 | Nested Therapeutics | Seed Round | 35M |
| 2/2006 | Ablation Frontiers | Series B | 15.1M |
| 6/2013 | ForSight Labs | Series B | 9.3M |
| 11/2017 | Nouscom | Series B | 48.8M |
| 3/2009 | NovaLign Orthopaedics | Series B | 10M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 1/2006 | Ambrx | Series B | 5M |
| 7/2006 | GluMetrics | Series B | 9M |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 7/2019 | Century Therapeutics | Series A | 250M |
| 5/2014 | Ceterix Orthopaedics | Series B | 18M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 1/2014 | Intuity Medical | Venture Round | 5.5M |
| 10/2008 | Lutonix | Series B | 20M |
| 3/2012 | Sequent Medical | Series C | 26M |
| 10/2013 | Inceptus | Series A | 4.7M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 11/2012 | CardiAQ Valve Technologies | Series B | 37.3M |
| 7/2005 | Nanoplex Technologies | Series B | 2.5M |
| 12/2005 | Acclarent | Series B | 25M |
| 5/2004 | NeoVista | Series A | 2M |
| 2/2013 | Nuvaira | Series C | 10M |
| 11/2016 | Intuity Medical | Venture Round | 0 |
| 1/2001 | Salmedix | Series A | - |
| 12/2008 | Hotspur Technologies | Series A | 1.3M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 3/2014 | PIQUR Therapeutics | Series A | 32M |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 6/2008 | ROX Medical | Series C | 33M |
| 10/2013 | Inari Medical | Series A | 4.7M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 6/2018 | Akero Therapeutics | Series A | 65M |
| 3/2005 | Ambrx | Series A | 23.4M |
| 11/2006 | Intersection Medical Inc | Series B | 5M |
| 8/2011 | Intuity Medical | Series D | 12M |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 9/2015 | Veran Medical Technologies | Venture Round | 0 |
| 9/2014 | Ivantis | Series B | 25M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 1/2009 | Synosia Therapeutics | Series B | 0 |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 1/2009 | AlterG | Series B | 8M |
| 1/2010 | The Foundry | Series A | 3M |
| 4/2012 | Five Prime Therapeutics | Private Equity Round | 10M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 10/2011 | Realeve | Series C | 32M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 6/2013 | Veracyte | Series C | 28M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 8/2001 | Insulet | Series B | 11M |
| 2/2019 | Nuvaira | Equity | 79M |
| 11/2002 | Skylight Healthcare Systems | Series B | 7.8M |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 11/2003 | NeoGuide Systems | Series B | 0 |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 12/2017 | Respicardia | Venture Round | 0 |
| 1/2017 | Halio | Series C | 65M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 1/2017 | Therachon | Series A | 5M |
| 8/2020 | T-knife | Series A | 78.4M |
| 4/2014 | AAVLife | Series A | 12M |
| 8/2018 | Therachon | Series B | 60M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 9/2021 | iECURE | Series A | 50M |
| 7/2013 | Audentes Therapeutics | Series A | 30M |
| 6/2015 | Sebacia | Series C | 12M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 4/2014 | Sequent Medical | Series D | 20M |
| 4/2011 | Halscion, Inc. | Venture Round | 3.5M |
| 8/2006 | ImpediMed | Venture Round | 3.4M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 7/2004 | LipoSonix | Series C | 27M |
| 4/2007 | NovaCardia | Series B | 18M |
| 10/2004 | Concuity | Venture Round | 8.3M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2019 | Passage Bio | Series B | 110M |
| 8/2008 | Glaukos | Series D | 35M |
| 10/2013 | Immune Design | Series C | 49M |
| 7/2006 | Ambrx | Series C | 52M |
| 6/2009 | Nexis Vision | Series B | 12M |
| 12/2000 | Skylight Healthcare Systems | Series A | - |
| 8/2021 | Jnana Therapeutics | Series B | 50M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 6/2002 | Spiration | Series D | 22M |
| 11/2006 | Neurotech | Series B | 0 |
| 11/2017 | Oyster Point Pharmaceuticals | Series A | 22M |
| 7/2020 | Bright Peak Therapeutics | Series A | 35M |
| 9/2015 | Therachon | Series A | 35M |
| 1/2020 | VectivBio | Series A | 35M |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 10/2020 | RayzeBio | Series A | 45M |
| 9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
| 10/2015 | Turnstone Biologics | Series A | 11.3M |
| 7/2015 | PIQUR Therapeutics | Series A | 19M |
| 8/2012 | AlterG | Series C | 10M |
| 1/2008 | Inogen | Series E | 12.7M |
| 9/2012 | Rox Medical | Series D | 6M |
| 2/2007 | Trius Therapeutics | Series A | 20M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 10/2010 | Synosia Therapeutics | Series C | 0 |
| 1/2007 | Synosia Therapeutics | Venture Round | 32.5M |
| 10/2009 | SpaceOAR | Series B | 6.1M |
| 11/2006 | Impedance Cardiology Systems | Series B | 5M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 4/2014 | RedBrick Health | Venture Round | 7.5M |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 11/2021 | ViaLase | Series A | 27.3M |
| 1/2017 | Ebb Therapeutics | Series B | 0 |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2007 | Inogen | Series D | 22M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 2/2017 | Vividion Therapeutics | Series A | 50M |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 3/2018 | Inari Medical | Series C | 20.9M |
| 2/2019 | Oyster Point Pharmaceuticals | Series B | 0 |
| 3/2008 | Spiration | Series G | 18.5M |
| 5/2014 | Anokion | Series A | 37.5M |
| 2/2007 | Vantage Oncology | Series D | 0 |
| 12/2001 | Pharmion | Venture Round | 65M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 11/2022 | iECURE | Series A | 0 |
| 9/2010 | Okairos | Series B | 20.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 9/2008 | ForteBio | Series C | 25M |
| 12/2017 | Jnana Therapeutics | Series A | 50M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 3/2009 | NeoVista | Series D | 18M |
| 6/2009 | Ocular Therapeutix | Series C | 15M |
| 7/2008 | Immune Design | Series A | 18M |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 10/2002 | Insulet | Series C | 22M |
| 10/2002 | Pharmion | Venture Round | 40M |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 8/2021 | T-knife | Series B | 110M |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 11/2006 | NewHope Bariatrics | Private Equity Round | 18.5M |
| 2/2018 | Quentis | Series A | 48M |
| 12/2019 | Pipeline Therapeutics | Series B | 0 |
| 9/2008 | Microfabrica | Series B | 22.5M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 8/2006 | Vantage Oncology | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 5/2005 | Vantage Oncology | Series C | 0 |
| 5/2020 | Monte Rosa Therapeutics | Series A | 32.5M |
| 4/2007 | Acclarent | Series C | 35M |
| 6/2021 | Stablix | Series A | 63M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 6/2004 | Vantage Oncology | Series B | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2004 | Spiration | Series E | 0 |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 4/2021 | Capsida | Series A | 50M |
| 9/2014 | Zyga Technology | Series D | 2M |
| 3/2002 | Phenomix | Series A | 12M |
| 3/2004 | Insulet | Series D | 35.5M |
| 9/2014 | AcuFocus | Venture Round | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 10/2003 | Biospect | Series B | 27M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 6/2004 | Inogen | Series B | 6M |
| 2/2009 | WaveTec Vision | Series C | 20.1M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 5/2011 | WaveTec Vision | Series D | 15.9M |
| 9/2007 | OpGen | Venture Round | 0 |
| 7/2017 | Sebacia | Series D | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2010 | Groove Biopharma | Series A | 3.9M |
| 7/2010 | Immune Design | Series B | 32M |
| 1/2008 | Confirma | Series C | 0 |
| 10/2005 | ForteBio | Series B | 17.3M |
| 7/2017 | Venatorx Pharmaceuticals | Series B | 42M |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 2/2006 | Insulet Corporation | Series E | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2010 | Intuity Medical | Series D | 64M |
| 5/2007 | WaveTec Vision | Series B | 13M |
| 1/2004 | Intuity Medical | Series B | 0 |
| 6/2021 | LENZ Therapeutics | Series A | 47M |
| 6/2020 | Lycia Therapeutics | Series A | 50M |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 4/2006 | Spiration | Series F | 13.4M |
| 1/2004 | Novacea | Series C | 35M |
| 9/2020 | Graphite Bio | Series A | 45M |
| 11/2002 | Novacea | Series B | 36M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 10/2008 | Respicardia | Series B | 0 |
| 1/2011 | Ocular Therapeutix | Series C | 6M |
| 2/2017 | Tarveda Therapeutics | Series D | 30M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 11/2001 | ParAllele Bioscience | Series A | - |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 11/2011 | AcuFocus | Private Equity Round | 0 |
| 6/2008 | Cameron Health | Series E | 0 |
| 4/2015 | Twelve | Series C | 35M |
| 4/2008 | Bird Rock Bio | Series A | 8M |
| 4/2013 | RedBrick Health | Private Equity Round | 14M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 6/2013 | Ocular Therapeutix | Series D | 23.8M |
| 12/2015 | Kyras Therapeutics | Series A | - |
| 2/2011 | Glaukos | Series E | 0 |
| 9/2006 | NeoVista | Series B | 26M |
| 10/2021 | Tentarix Biotherapeutics | Series A | 50M |
| 8/2012 | ForSight VISION5 | Venture Round | 8M |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 3/2009 | LensX Lasers | Series B | 22.4M |
| 4/2014 | ForSight VISION5 | Equity | 15M |
| 4/2014 | ForSight Labs | Series C | 15M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 5/2018 | Lava Therapeutics | Series A | 18.7M |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 11/2016 | Turnstone Biologics | Series B | 0 |
| 4/2009 | RedBrick Health | Series C | 15M |
| 5/2009 | Realeve | Series B | 20M |
| 8/2011 | RedBrick Health | Series D | 5M |
| 6/2010 | Veracyte | Series B | 28M |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 1/2007 | AcuFocus | Series D | 0 |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 11/2002 | Vantage Oncology | Series A | 9M |
| 12/2008 | CELLutions Biosystems | Series B | 8.8M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 6/2017 | Monteris Medical | Series C | 26.6M |
| 12/2015 | Inception IBD | Series A | 14.1M |
| 12/2007 | RedBrick Health | Series B | 15M |
| 3/2016 | Aprea | Series B | 50.6M |
| 11/2009 | Standard BioTools | Venture Round | 0 |
| 8/2020 | Matterhorn Biosciences | Venture Round | 30M |
| 12/2013 | Inception Sciences | Series A | 10M |
| 5/2001 | CardioNow | Series C | 6M |
| 1/2008 | Benvenue Medical | Series B | 15M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 11/2003 | Cameron Health | Series B | 29M |
| 9/2010 | Nuvaira | Series A | 3M |
| 6/2012 | Halscion, Inc. | Debt Financing | 4.3M |
| 10/2005 | Cameron Health | Series C | 15M |
| 12/2000 | Confirma | Series B | 12M |
| 9/2002 | Glaukos | Series A | 10M |
| 5/2008 | Novasys Health | Venture Round | 49.5M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 9/2006 | NovaCardia | Series B | 48M |
| 6/2004 | Aria Biosystems | Series A | 5.5M |
| 4/2014 | Nuvaira | Series D | 42M |
| 3/2008 | Ocular Therapeutix | Series B | 6M |
| 12/2016 | BlueRock Therapeutics | Series A | 225M |
| 5/2008 | Novasys Medical, Inc. | Series D | 49.5M |
| 9/2005 | Kythera Biopharmaceuticals | Seed Round | 1M |
| 4/2008 | Anaphore | Venture Round | 8M |
| 1/2009 | Anaphore | Series A | 25M |
| 4/2005 | NovaCardia | Series A | - |
| 12/2011 | Groove Biopharma | Series B | 6M |
| 4/2009 | Ambrx | Series D | 10M |
| 12/2018 | Black Diamond Therapeutics | Series A | 20M |
| 10/2012 | Cotera | Venture Round | 5M |
| 1/2004 | Standard BioTools | Series D | 21M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 1/2007 | Standard BioTools | Series E | 0 |
| 1/2011 | SpaceOAR | Debt Financing | 3M |
| 12/2016 | Veran Medical Technologies | Venture Round | 31M |
| 10/2009 | Halscion, Inc. | Venture Round | 6M |
| 9/2003 | ParAllele Bioscience | Series B | 22.5M |
| 6/2009 | Anaphore | Series A | 13M |
| 9/2019 | Anokion | Series B | 40M |
| 3/2012 | OpGen | Series C | 0 |
| 8/2007 | MedManage Systems | Series E | 5M |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 11/2001 | Standard BioTools | Series C | 34M |
| 3/2013 | Novira Therapeutics | Series A | 0 |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 4/2014 | CRISPR Therapeutics | Series A | 25M |
| 10/2020 | VectivBio | Equity | 110M |
| 6/2007 | CELLutions Biosystems | Series B | 7M |
| 2/2011 | Ocular Therapeutix | Series D | 14M |
| 7/2006 | Cameron Health | Series D | 31M |
| 10/2012 | Cerephex | Series A | 5.9M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 7/2008 | OraMetrix | Series C | 0 |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 11/2011 | Hicuity Health | Series D | 0 |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 12/2006 | NeoVista | Series C | 41M |
| 1/2009 | Bird Rock Bio | Series A | 25M |
| 10/2007 | Vital Therapies | Series C | 28.1M |
| 4/2004 | MedManage Systems | Series C | 6M |
| 11/2008 | CodeRyte | Series D | 0 |
| 8/2012 | Intuity Medical | Venture Round | 12M |
| 1/2017 | Jecure Therapeutics | Series A | 20M |
| 8/2006 | Intuity Medical | Series C | 20M |
| 6/2002 | Intuity Medical | Series A | 3M |
| 4/2004 | ROX Medical | Series A | 3.6M |
| 9/2016 | Rox Medical | Series E | 40M |
| 3/2009 | Rennovia | Series A | 16.3M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 6/2015 | Inari Medical | Series B | 12.4M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 1/2019 | Halio | Series D | 100M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 6/2002 | Salmedix | Series B | 27.5M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 12/2003 | Confirma | Venture Round | 3M |
| 9/2010 | OpGen | Series B | 0 |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 8/2019 | Chinook Therapeutics | Series A | 65M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 11/2022 | iECURE | Series A | 0 |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
